| Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... The Lancet 393 (10185), 2051-2058, 2019 | 1584 | 2019 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... Journal of Clinical Oncology 38 (25), 2830, 2020 | 852 | 2020 |
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival S Harrow, V Papanastassiou, J Harland, R Mabbs, R Petty, M Fraser, ... Gene therapy 11 (22), 1648-1658, 2004 | 404 | 2004 |
| UK consensus on normal tissue dose constraints for stereotactic radiotherapy GG Hanna, L Murray, R Patel, S Jain, KL Aitken, KN Franks, N Van As, ... Clinical Oncology 30 (1), 5-14, 2018 | 244 | 2018 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial DA Palma, R Olson, S Harrow, RJM Correa, F Schneiders, CJA Haasbeek, ... BMC cancer 19, 1-15, 2019 | 191 | 2019 |
| Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial DA Palma, RA Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, ... International Journal of Radiation Oncology, Biology, Physics 102 (3), S3-S4, 2018 | 118 | 2018 |
| Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes S Harrow, DA Palma, R Olson, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... International Journal of Radiation Oncology* Biology* Physics 114 (4), 611-616, 2022 | 103 | 2022 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial R Olson, L Mathews, M Liu, D Schellenberg, B Mou, T Berrang, S Harrow, ... BMC cancer 20, 1-12, 2020 | 89 | 2020 |
| Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset V Moiseenko, J Wu, A Hovan, Z Saleh, A Apte, JO Deasy, S Harrow, ... International Journal of Radiation Oncology* Biology* Physics 82 (3), 1108-1114, 2012 | 70 | 2012 |
| Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic C Faivre-Finn, JD Fenwick, KN Franks, S Harrow, MQF Hatton, C Hiley, ... Clinical Oncology 32 (8), 481-489, 2020 | 63 | 2020 |
| Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment G Eeson, M Foo, S Harrow, G McGregor, J Hay The American journal of surgery 201 (5), 628-633, 2011 | 62 | 2011 |
| Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the … R Olson, S Senan, S Harrow, S Gaede, A Louie, C Haasbeek, L Mulroy, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 943-947, 2019 | 53 | 2019 |
| UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy P Diez, GG Hanna, KL Aitken, N Van As, A Carver, RJ Colaco, J Conibear, ... Clinical Oncology 34 (5), 288-300, 2022 | 49 | 2022 |
| Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study K Haslett, K Franks, GG Hanna, S Harden, M Hatton, S Harrow, ... BMJ open 6 (4), e010457, 2016 | 41 | 2016 |
| Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial XM Qu, Y Chen, GS Zaric, S Senan, RA Olson, S Harrow, A John-Baptiste, ... International Journal of Radiation Oncology* Biology* Physics 109 (5), 1176-1184, 2021 | 33 | 2021 |
| Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma ATM Mace, SJ Harrow, I Ganly, SM Brown Acta oto-laryngologica 127 (8), 880-887, 2007 | 33 | 2007 |
| An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer R Rulach, D Ball, KLM Chua, M Dahele, D De Ruysscher, K Franks, ... Advances in radiation oncology 6 (2), 100653, 2021 | 27 | 2021 |
| Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer M Stares, TE Ding, C Stratton, F Thomson, M Baxter, H Cagney, ... ESMO open 7 (2), 100445, 2022 | 26 | 2022 |
| Re-irradiation for locally recurrent lung cancer: Evidence, risks and benefits R Rulach, GG Hanna, K Franks, J McAleese, S Harrow Clinical Oncology 30 (2), 101-109, 2018 | 25 | 2018 |
| An assessment of cone beam CT in the adaptive radiotherapy planning process for non-small-cell lung cancer patients A Duffton, S Harrow, C Lamb, M McJury The British Journal of Radiology 89 (1062), 20150492, 2016 | 25 | 2016 |
